November 2016 - Page 4 of 9

MondayNov 21, 2016 9:49 am

Park Place Energy (PKPL) Expects Exponential Growth after Turkish Assets Acquisition

Park Place Energy, Inc. (OTCQB: PKPL), a Texas-based gas and oil exploration company focused on running international development and exploration projects, anticipates significant growth in terms of cash flow and share prices once it completes the acquisition of three oil and gas companies in Turkey next month. The company, which already has an established presence and offices in the Balkan region via its gas exploration in northeast Bulgaria, entered a purchase agreement with Tiway Oil B.V. in December of last year for the acquisition of three Tiway subsidiaries controlling three oil and gas explorations in Turkey – one offshore and…

MondayNov 21, 2016 9:16 am

GainClients, Inc. (GCLT) is “One to Watch”

GainClients, Inc. (OTC: GCLT) is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company’s innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data. The company’s main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information…

FridayNov 18, 2016 2:32 pm

Ampio Pharmaceuticals, Inc. (AMPE) Targeting Common Inflammatory Conditions with Two Late-Stage Product Candidates

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. The company’s development pipeline currently features two product candidates advancing through late-stage clinical trials in the United States, including Ampion™ for the treatment of osteoarthritis of the knee (OAK) and Optina™ for the treatment of diabetic macular edema (DME). Osteoarthritis, the most common form of arthritis, currently affects more than 100 million people in the United States alone, with over 48 million suffering from OAK. Meanwhile,…

FridayNov 18, 2016 11:06 am

Medical Transcription Billing, Corp. (MTBC) Announces Monthly Dividend on Series A Preferred Stock

Before the opening bell, Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP) announced that its board of directors has declared monthly cash dividends for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock for December, January and February. These monthly dividends will be valued at roughly $0.23 per share, or 11% of the $25 per share liquidation preference, and will be made payable on the 15th day of the following month. The applicable record date for the newly-announced dividends will be the last day of the relevant calendar month. News of the dividends comes just over a week after MTBC…

FridayNov 18, 2016 9:49 am

CytoSorbents Corp. (CTSO) is “One to Watch”

November has been a promising month for CytoSorbents Corp. (NASDAQ: CTSO), a critical care immunotherapy company. The New Jersey-based company, specializing in blood purification to control deadly inflammation in critically ill and cardiac surgery patients, reported its financial results for the third quarter ended September 30, 2016. CTSO reported that product sales for the third quarter of this year were up to $2.14 million, a new record, marking the sixth quarter in a row to show substantial growth with sales up by 100% from 2015’s $1.07 million. The jump was attributed to increases in both direct sales and sales through…

ThursdayNov 17, 2016 3:58 pm

Inovio Pharmaceuticals, Inc. (INO) opens New Front Line in War against Cancer & Infectious Diseases with DNA Vaccines

Over 2,000 years ago, Plato, in his immortal Socratic dialogue, had the great philosopher express his astonishment at the new diseases plaguing Athenian society and their bizarre and horrible names. Our position today is very similar. Strange, horrible afflictions with bizarre, frightening names like cancer, Ebola and Zika, unknown or unrecognized until modern times, threaten us with epidemics and pandemics. For a hundred years or so, we’ve fought them off with traditional vaccines and pharmaceuticals. Now, a new battlefront is set to open with the advent of DNA vaccines from companies like Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Traditional vaccines stimulate…

ThursdayNov 17, 2016 2:35 pm

Aegis Capital Supports ‘Buy’ Rating, Higher Stock Price Target for Progenics (PGNX) Following Strong Q3 Results

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a company focused on the development of innovative treatments and therapies for cancer, in particular prostate cancer, recently released its financial results for the third quarter of 2016, reporting higher revenue and net income compared to the third quarter of 2015. The growth can be primarily attributed to the FDA approval and U.S. commercial launch of its flagship product, oral Relistor®, for the treatment of opioid induced constipation in patients suffering from chronic non-cancer pain, according to an Aegis Capital Corp. analysis (http://nnw.fm/K8l26) released on November 8, one day after the Q3 results. The Aegis…

ThursdayNov 17, 2016 2:13 pm

Nektar Therapeutics (NKTR) is “One to Watch”

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company in the business of developing new medicines for people living with life changing conditions, now helps more than nine million patients worldwide. Nektar also offers a proprietary pipeline made up of drug candidates for oncology, pain, anti-infectives, and immunology. The company has 12 approved products, including Movantik, Adynovate, and Onzeald. Movantik, which is used for the treatment of opioid induced constipation, was approved for sale in both the U.S. and Europe in 2014, allowing Nektar to see a significant increase in sales and royalty payments. Adynovate, used in the treatment of hemophilia A…

ThursdayNov 17, 2016 12:54 pm

Singlepoint, Inc. (SING) Subsidiary SingleSeed Aiming to Help Cannabis Business Owners Thrive

The U.S. cannabis market is expected to continue and even speed up its exponential growth as a result of last week’s vote to legalize recreational or medical marijuana in eight more states. This is good news for an industry that is already growing at a fast pace, being set to exceed $7 billion this year, according to ArcView Research estimates. The trend is likely to continue, as experts predict the marijuana market to reach roughly $22 billion by 2020 and $50 billion by 2026. But even if the market is growing so quickly, legal businesses operating in the sector still…

ThursdayNov 17, 2016 12:33 pm

Monaker Group (MKGI) Set to Capitalize on This Year’s Thanksgiving Celebrations

This Thanksgiving, AAA, North America’s largest motoring and leisure travel organization, is expecting over one million more Americans to travel. According to the company’s 2016 Thanksgiving Holiday Travel Forecast, there will be more than 48.7 million travelers, marking the highest Thanksgiving holiday travel volume since 2007. Travel has gone up 1.9% this year alone, leading to a 29% increase of travelers during Thanksgiving over the past eight years. According to the report and its attached infographic, 89.4% of people will be traveling by car, a 12.5% increase from the 2001 to 2015 average. In addition, air travel has risen 10%…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: November 2016